| Similar Articles |
|---|
 |
BusinessWeek
March 12, 2007
Gene G. Marcial |
SuperGen Is Looking Healthier Biotechs are gaining traction this year as fund managers discover many with viable products that are still underpriced.   |
The Motley Fool
October 18, 2007
Brian Lawler |
MGI's Quiet Gains The specialty pharma notches a healthy third-quarter and should keep performing well into the future. Investors, take note. |
The Motley Fool
September 3, 2004
Charly Travers |
MGI Pharma's Shopping Spree The company is filling out its drug pipeline with acquisitions. |
The Motley Fool
July 24, 2007
Brian Lawler |
MGI Flies Shares of MGI Pharma rise after positive second-quarter results and a bright outlook for the coming months. |
The Motley Fool
December 11, 2007
Brian Lawler |
The MGI Deal Makes Sense MGI Pharma announces it is being acquired by Japanese pharma giant Eisai for $3.9 billion. |
The Motley Fool
November 30, 2007
Brian Lawler |
MGI's Turn for "Strategic Alternatives" MGI Pharma is the latest in a growing list of drugmakers looking for someone to acquire them. The company may be a relatively more attractive takeover target than other drugmakers, because it's two lead drugs are unpartnered in the U.S. |
The Motley Fool
October 23, 2006
Brian Lawler |
MGI's Anonymous Growth If there's a value stock in the pharma world, this may be it. |
The Motley Fool
July 3, 2008
Brian Lawler |
Celgene Savors the Schadenfreude Bad news for a rival is a bonanza for drugmaker Celgene. |
BusinessWeek
October 11, 2004
Gene G. Marcial |
Can Axonyx Help Treat Alzheimer's? With a number of products in its pipeline and $93 million in cash, the company "heads my list in biotechs," says the top biotech analyst at Rodman & Renshaw. Its Phenserine, which is already in Phase 3 trials, may be a valuable weapon in combatting Alzheimer's. |
